NCT05965622 (Cost)-Effectiveness of ABFT for Suicidal Youth.
| NCT ID | NCT05965622 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Condition | Suicidal Ideation |
| Study Type | INTERVENTIONAL |
| Enrollment | 138 participants |
| Start Date | 2023-10-05 |
| Primary Completion | 2025-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 138 participants in total. It began in 2023-10-05 with a primary completion date of 2025-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Young adults who attempt to kill themselves is a common and serious mental health problem worldwide and certainly in Belgium and the Netherlands. Fatal suicide is the leading cause of death among young adults. It has devastating consequences both for the young adults themselves and for their families. It also has substantial economic costs. However, up until now, there is little research on the treatment of suicidality among young adults. The current psychological therapy approaches and drug treatments for young people at very high risk of fatal suicide attempts have only limited success. Increasing evidence indicates the importance of involving significant others in treatment and the importance of the unfulfilled need for belonging and secure attachment. The WHO recommends involving significant others in the treatment of suicidal young adults. However, in Belgium and the Netherlands, there is little knowledge on the effectiveness of family based treatments. Attachment Based Family Therapy, or ABFT, was shown to work well in several studies in the US. Also in Belgium and the Netherlands, ABFT is being used to treat suicidal young adults. However, how well it works compared to the current treatment and if it provides good value for money have not been studied in young adults. In the proposed study the investigators will test, in a real-life situation, whether ABFT works better than the current treatment and if it provides good value for money. This study is a collaboration between the Netherlands and Belgium and 6 or 7 sites will participate from each country. Sites can be hospitals, mental health centres, student health centres or private practices. Participants (138 individuals) are young adults between 18 and 25 years old who have frequent thoughts about killing themselves, and who seek mental health treatment. The investigators predict that, compared to current treatment, ABFT will reduce suicidal thoughts and suicide attempts and that this improvement will be maintained over time, and that it will be better value for money. The project will contribute to improving care for suicidal young adults with high suicide risk. Results will inform clinical guidelines and policymakers and improve the treatment of young adults with a high risk for fatal suicide, and their families.
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 25. * A score above 31 on the SIQ-JR (the cut-off for suicidality). * Have at least one primary parent or caregiver that participates in the assessment and treatment. This could be a biological parent, stepparent, grandparent, other relative, or a foster parent. Exclusion Criteria: * Other DSM-5 disorders: substance dependency: severe alcohol or cannabis use disorder, all other substances: modest or severe substance use disorder. * Severe conduct disorder. * Evidence of psychotic features or prior psychosis (assessed with the SCID-5-S). * Severe cognitive impairment (e.g., mental retardation, severe developmental disorders) as evidenced by educational records, parental report and/or clinical impression. * Other circumstances that might affect participation (e.g., severe medical disorder, relocation).
Contact & Investigator
Nadia van der Spek, PhD
STUDY DIRECTOR
Academic Medical Center (AMC)
Frequently Asked Questions
Who can join the NCT05965622 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 25 Years, studying Suicidal Ideation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05965622 currently recruiting?
Yes, NCT05965622 is actively recruiting participants. Contact the research team at c.l.bockting@amsterdamumc.nl for enrollment information.
Where is the NCT05965622 trial being conducted?
This trial is being conducted at Tongeren, Belgium, Ghent, Belgium, Kortenberg, Belgium, Leuven, Belgium and 9 additional locations.
Who is sponsoring the NCT05965622 clinical trial?
NCT05965622 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). The principal investigator is Nadia van der Spek, PhD at Academic Medical Center (AMC). The trial plans to enroll 138 participants.